Pharmacogenetic variability in neuronal nicotinic receptor-mediated antinociception

Pharmacogenetics

Volumn 9, Issue 5, 1999, Pages 619-625

  Flores, Christopher M ^a   Wilson, Sonya G ^b   Mogil, Jeffrey S ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Analgesia; Epibatidine; Nicotine; Pain

Indexed keywords

ANALGESIC AGENT; ANTINOCICEPTIVE AGENT; EPIBATIDINE; MECAMYLAMINE; NICOTINIC RECEPTOR;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISPOSITION; DRUG EFFICACY; FEMALE; GENETIC VARIABILITY; HEREDITY; INBRED STRAIN; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PAIN THRESHOLD; PHARMACOGENETICS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALIA;

EID: 0032739296     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199910000-00008     Document Type: Article

References (29)

1. Badio B, Daly JW. Epibatidine, a potent analgetic and nicotinic agonist. Mol Pharmacol 1994; 45:563-569.
2. Bannon AW, Decker MW, Holladay MW, Curzon P, Donnelly Roberts D, et al. Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science 1998; 279:77-81.
3. Belknap JK, Mogil JS, Helms ML, Richards SP, O'Toole LA, Bergeson SE, Buck KJ. Localization to proximal chromosome 10 of a locus influencing morphine-induced analgesia in crosses derived from C57BL/6 and DBA/2 mouse strains. Life Sci 1995: 57:PL117-PL124.
4. Ben-Bassat J, Peretz E, Sulman FG. Analgesimetry and ranking of analgesic drugs by the receptacle method. Arch Int Phamacodyn Ther 1959; 122:434-447.
5. Benowitz NL, Jacob P III. Individual differences in nicotine kinetics and metabolism in humans. NIDA Res Monograph 1997; 173:48-64.
6. Collins AC, Miner LL, Marks MJ. Genetic influences on acute responses to nicotine and nicotine tolerance. Pharmacol Biochem Behav 1988; 30:269-278.
7. Davis L, Pollock LJ, Stone TT. Visceral pain. Surg Gynecol Obstet 1932; 55:418-426.
8. Elmslie FV, Rees M, Williamson MP, Kerr M, Kjeldsen MJ, Pang KA, et al. Genetic mapping of a major susceptibility locus for juvenile myoclonic epilepsy on chromosome 15q. Hum Mol Gen 1997; 6:1329-1334.
9. Falconer DS, Mackay TFC. Introduction to quantitative genetics. Essex, UK: Longman; 1996.
10. Flores CM, Hargreaves KM. Neuronal nicotinic receptors: new targets in the treatment of pain. In: Arneric SP, Brioni JD, editors. Neuronal nicotinic receptors: pharmacology and therapeutic opportunities. Wiley-Liss Inc; 1998. pp. 359-378.
11. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 1997; 94:587-592.
12. Hegmann JP, Possidente B. Estimating genetic correlations from inbred strains. Behav Genet 1981; 11:103-114.
13. Lander ES, Schork NJ. Genetic dissection of complex traits. Science 1994; 265:2037-2048.
14. Marks MJ, Burch JB, Collins AC. Genetics of nicotine response in four inbred strains of mice. J Pharmacol Exp Ther 1983; 226:291-302.
15. Marks MJ, Ronim E, Campbell SM, Collins AC. Variation of nicotinic binding sites among inbred strains. Pharmacol Biochem Behav 1989; 33:679-689.
16. Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidalion by human liver microsomes. J Pharmacol Exp Ther 1997; 282:1608-1614.
17. Mogil JS, Sadowski B, Belknap JK. The role of the serotonin-IB receptor in genetic sensitivity to opiate analgesia in mice. Soc Neurosci Abstr 1995; 21:1415.
18. Mogil JS, Sternberg WF, Marek P, Sadowski B, Belknap JK, Liebeskind JC. The genetics of pain and pain inhibition. Proc Natl Acad Sci USA 1996; 93:3048-3055.
19. Mogil JS, Wilson SG, Bon K, Lee SE, Chung K, Raber P. et al. Heritability of nociception. I. Responses of 11 inbred mouse strains on 12 measures of nociception. Pain 1999; 80:67-82.
20. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 1996; 24:1212-1217.
21. Persson K, Sjostrom S, Sigurdardottir I, Molnar V, Hammarlund-Udenaes M, Rane A. Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in 10 extensive metabolisers and one poor metaboliser of dextromethorphan. Br J Clin Pharmacol 1995; 39:182-186.
22. Petersen DR, Norris KJ, Thompson JA. A comparative study of the disposition of nicotine and its metabolites in three inbred strains of mice. Drug Metab Dispos 1984; 12:725-731.
23. Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 1996; 51:289-295.
24. Seale TW, Nael R, Basmadjian G. Inherited, selective hyporesponsiveness to the analgesic action of nicotine in mice. Neuroreport 1996; 8:191-195.
25. Seale TW, Nael R, Singh S, Rasmadjian G. Inherited, selective hypoanalgesic response to cytisine in the tail-flick test in CF-1 mice. Neuroreport 1998; 9:201-205.
26. Spande TF, Garraffo HM, Edwards MW, Yeh HJC, Pannel L, Daly JW. Epibatidine: a novel (chloropyridyl)azabicycloheptane with potent analgesic activity from an Ecuadoran poison frog. J Am Chem Soc 1992; 114:3475-3478.
27. Steinlein O, Sander T, Stoody J, Kretz R, Janz D, Propping P. Possible association of a silent polymorphism in the neuronal nicotinic acetylcholine receptor subunit alpha4 with common idiopathic generalized epilepsies. Am J Med Gen 1997; 74:445-449.
28. Tallarida RJ. Murray RB. Manual of pharmacologic calculation. New York: Springer-Verlag: 1981.
29. Yun CH, Wood M, Wood AJ, Guengerich FP. Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4. An explanation of the variable elimination clearance. Anesthesiology 1992; 77:467-474.